跨性别者在HIV疫苗试验网络1-2a期试验中的描述性分析
分析2009至2014年美国与秘鲁HVTN的1-2a期试验中694名参与者,其中跨性别者13人(2%)、顺性别者681人(98%)。跨性别者参与动机以利他为主,能维持低HIV感染风险特征,依从性高,未因性别认同出现疫苗接种中止。
要点
- 跨性别者占试验参与者2%,参与动机100%为帮助找到有效疫苗和帮助社区。
- 跨性别者报告既往病症与顺性别者存在显著差异(p=0.004),约10%与性别认同相关。
- 跨性别者激素治疗使用(p<0.001)和心理健康药物使用(p=0.007)与顺性别者差异显著。
核心结论
- 跨性别者参与动机为利他,能维持低HIV感染风险特征并遵循试验程序,保留率高。
- 跨性别者与顺性别者HIV发病率无统计学显著差异。
研究设计与样本
- 分析2009至2014年美国与秘鲁HVTN的1-2a期试验中694名参与者数据。
- 按性别认同与出生指定性别是否一致分为跨性别组(13人)和顺性别组(681人)进行比较。
主要发现
- 681人(98%)为顺性别,13人(2%)为跨性别;平均年龄25岁,16%为西班牙裔,69%为白人。
- 入组原因:帮助找到有效疫苗(跨性别100%;顺性别98%)和帮助社区(跨性别100%;顺性别96%)。
- 既往病症报告在性别认同间差异显著(p=0.004),跨性别者约10%的既往病症与性别认同相关。
- 激素治疗使用差异显著(p<0.001),心理健康药物使用差异显著(p=0.007)。
- 跨性别者漏访率2.1%、疫苗接种中止率0;顺性别者漏访率3%、疫苗接种中止率7.1%。
临床怎么用
- 在HIV预防疫苗早期试验中可纳入维持低HIV感染风险特征的跨性别者,其依从性和保留率与顺性别者相当。
局限性
- 跨性别者样本量小(13人),可能限制统计效能和结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV disproportionately impacts transgender populations globally, creating challenges to inclusion in trials requiring low HIV risk profiles (LHRP) for acquisition. Our knowledge of transgender individuals with LHRP is limited. We conducted an analysis of transgender and cisgender individuals in HVTN trials enrolling individuals with LHRP. METHODS: We analyzed data from 694 participants enrolled in the phase 1-2a HVTN trials in the US and Peru from 2009 to 2014 that included individuals who reported gender identity (GI) differing from assigned birth sex (transgender [TG]), and compared them with those who reported a congruent GI (cisgender [CG]). RESULTS: 681 participants (98%) were CG and 13 (2%) were TG. Mean age was 25 years. 16% were Hispanic and most (69%) were White. Reasons for enrolling included to help find an effective vaccine (TG 100%; CG 98%) and help their community (TG 100%; CG 96%). Significant differences by GI were observed in reported pre-existing conditions (p = 0.004); however, approximately 10% of pre-existing conditions reported by TG were GI-related (e.g., gender dysphoria). Significant differences were observed in hormone therapy use (p < 0.001) and mental health medications (p = 0.007). Retention was excellent with 2.1% missed visits and no discontinuations of vaccination for TG and 3% missed visits and 7.1% discontinuations among CG. There was no statistically significant difference in HIV incidence. CONCLUSIONS: Primary reasons for participation were altruistic for all participants. Comparable to CG counterparts, TG participants maintained LHRP, followed trial procedures, and had high retention, facilitating meaningful early phase HIV preventive vaccine trial contributions.
引用
- Andrasik M, Grove D, Broder G, et al. A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru. Vaccine. 2019. PMID: 31176538. doi:10.1016/j.vaccine.2019.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。